573 related articles for article (PubMed ID: 3257158)
1. Effect of continuous administration of interleukin 2 on active specific chemoimmunotherapy with extracted tumor-specific transplantation antigen and cyclophosphamide.
Naito K; Pellis NR; Kahan BD
Cancer Res; 1988 Jan; 48(1):101-8. PubMed ID: 3257158
[TBL] [Abstract][Full Text] [Related]
2. Tumor-specific chemoimmunotherapy of murine fibrosarcoma using tumor-specific transplantation antigen, cyclophosphamide, and interleukin-2.
Naito K; Nomi S; Komichi H; Ueda Y; Yamagishi H; Oka T; Pellis NR; Kahan BD
Cancer Detect Prev; 1992; 16(5-6):321-7. PubMed ID: 1361881
[TBL] [Abstract][Full Text] [Related]
3. Intrasplenic administration of interleukin-2 to potentiate specific chemoimmunotherapy in tumor-bearing mice.
Nomi S; Naito K; Kahan BD; Pellis NR
Cancer Res; 1986 Nov; 46(11):5606-10. PubMed ID: 2875791
[TBL] [Abstract][Full Text] [Related]
4. Specific chemoimmunotherapy in tumor-bearing mice with extracted antigen, cyclophosphamide, and intrasplenic administration of interleukin-2.
Kahan BD; Nomi S; Pellis NR
Cancer; 1986 Feb; 57(3):477-83. PubMed ID: 3484658
[TBL] [Abstract][Full Text] [Related]
5. Active specific immunotherapy with extracted tumor-specific transplantation antigen, cyclophosphamide, and adoptive transfer of tumor-specific cytotoxic T-cell clones.
Naito K; Pellis NR; Kahan BD
Cell Immunol; 1988 Jan; 111(1):216-34. PubMed ID: 3257414
[TBL] [Abstract][Full Text] [Related]
6. Retardation of postsurgical metastases with the use of extracted tumor-specific transplantation antigens and cyclophosphamide.
Nomi S; Pellis NR; Kahan BD
J Natl Cancer Inst; 1984 Oct; 73(4):943-50. PubMed ID: 6237215
[TBL] [Abstract][Full Text] [Related]
7. Combination chemotherapy and IL-15 administration induce permanent tumor regression in a mouse lung tumor model: NK and T cell-mediated effects antagonized by B cells.
Chapoval AI; Fuller JA; Kremlev SG; Kamdar SJ; Evans R
J Immunol; 1998 Dec; 161(12):6977-84. PubMed ID: 9862733
[TBL] [Abstract][Full Text] [Related]
8. Intratumor gene expression after adoptive immunotherapy in a murine tumor model. Regulation of messenger RNA levels associated with the differential expansion of tumor-infiltrating lymphocytes.
Evans R; Kamdar SJ; Duffy T; Edison L
J Immunol; 1993 Jan; 150(1):177-84. PubMed ID: 8417123
[TBL] [Abstract][Full Text] [Related]
9. Immunotherapy of a carcinogen-induced murine sarcoma with soluble tumor-specific transplantation antigens.
Kahan BD; Tanaka T; Pellis NR
J Natl Cancer Inst; 1980 Nov; 65(5):1001-4. PubMed ID: 6159495
[TBL] [Abstract][Full Text] [Related]
10. Antitumor efficacy of lymphokine-activated killer cells and recombinant interleukin 2 in vivo: successful immunotherapy of established pulmonary metastases from weakly immunogenic and nonimmunogenic murine tumors of three district histological types.
Papa MZ; Mulé JJ; Rosenberg SA
Cancer Res; 1986 Oct; 46(10):4973-8. PubMed ID: 3489517
[TBL] [Abstract][Full Text] [Related]
11. Continuous intrasplenic interleukin-2 combined with antigen-specific chemoimmunotherapy.
Naito K; Pellis NR; Kahan BD
Arch Surg; 1986 Dec; 121(12):1415-20. PubMed ID: 3491596
[TBL] [Abstract][Full Text] [Related]
12. Immunotherapeutic effects of partially purified tumor-specific transplantation antigens on pulmonary metastases of a 3-methylcholanthrene-induced sarcoma in mice: a preliminary report.
Tanaka T; Pellis NR; Kahan BD
J Natl Cancer Inst; 1982 Nov; 69(5):1121-6. PubMed ID: 6957656
[TBL] [Abstract][Full Text] [Related]
13. Immunotherapy of murine sarcomas using lymphokine activated killer cells: optimization of the schedule and route of administration of recombinant interleukin-2.
Ettinghausen SE; Rosenberg SA
Cancer Res; 1986 Jun; 46(6):2784-92. PubMed ID: 3486038
[TBL] [Abstract][Full Text] [Related]
14. Ineffectiveness of adoptive chemoimmunotherapy with lymphokine-activated killer cells, interleukin-2, and cyclophosphamide on palpable intradermal murine bladder cancer.
Lee K; O'Donnell RW; Cockett AT
J Biol Response Mod; 1988 Feb; 7(1):43-53. PubMed ID: 3259620
[TBL] [Abstract][Full Text] [Related]
15. Effects of cancer immunotherapy with indomethacin and interleukin-2 on murine hemopoietic stem cells.
Saarloos MN; Khoo NK; Lala PK
Cancer Res; 1992 Dec; 52(23):6452-62. PubMed ID: 1423293
[TBL] [Abstract][Full Text] [Related]
16. Combined effects of chemotherapy and interleukin 2 in the therapy of mice with advanced pulmonary tumors.
Papa MZ; Yang JC; Vetto JT; Shiloni E; Eisenthal A; Rosenberg SA
Cancer Res; 1988 Jan; 48(1):122-9. PubMed ID: 3257159
[TBL] [Abstract][Full Text] [Related]
17. Donor T cells can be induced to grow and survive long term in vivo without previous host immunosuppression.
Chen W; Cheever MA
J Immunol; 1994 May; 152(10):4767-74. PubMed ID: 8176202
[TBL] [Abstract][Full Text] [Related]
18. Active specific chemoimmunotherapy of lymph-node metastasis from a poorly immunogenic murine fibrosarcoma.
Naito K; Oka T; Nomi S; Yamagishi H; Kahan BD
Jpn J Cancer Res; 1989 Nov; 80(11):1119-26. PubMed ID: 2514172
[TBL] [Abstract][Full Text] [Related]
19. Importance of cyclophosphamide-induced bystander effect on T cells for a successful tumor eradication in response to adoptive immunotherapy in mice.
Proietti E; Greco G; Garrone B; Baccarini S; Mauri C; Venditti M; Carlei D; Belardelli F
J Clin Invest; 1998 Jan; 101(2):429-41. PubMed ID: 9435316
[TBL] [Abstract][Full Text] [Related]
20. Biochemical characterization of 1-butanol-extracted murine tumor-specific transplantation antigens.
LeGrue SJ; Pellis NR; Riley LB; Kahan BD
Cancer Res; 1985 Jul; 45(7):3164-72. PubMed ID: 2408745
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
